Roche’s part IIb research of prasinezumab failed to fulfill main endpoint, however suggests doable medical profit in treating early-stage Parkinson’s illness
The PADOVA research confirmed a numerical delay in motor development and constructive…
Search
Have an existing account?
Sign In
Tag: IIb
